MXCT
MaxCyte, Inc. NASDAQ Listed Jul 30, 2021$1.21
+7.08%
vs $1.13
Mkt Cap $128.8M
52w Low $0.68
32.3% of range
52w High $2.33
50d MA $0.99
200d MA $1.21
P/E (TTM)
-2.9x
EV/EBITDA
—
P/B
0.8x
Debt/Equity
0.1x
ROE
-26.0%
P/FCF
-3.6x
RSI (14)
50.00
ATR (14)
$0.07
Beta
1.45
50d MA
$0.99
200d MA
$1.21
Avg Volume
1.1M
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
9713 Key West Avenue · Rockville, MD 20850 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.08 | -0.06 | +25.0% | 0.74 | -1.4% | -6.8% | +3.9% | -4.6% | -1.1% | +3.9% | — |
| Nov 12, 2025 | AMC | -0.11 | -0.12 | -9.1% | 1.58 | -3.8% | -4.4% | +4.6% | +3.2% | +4.9% | -0.6% | — |
| Aug 6, 2025 | AMC | -0.10 | -0.12 | -20.0% | 2.04 | -16.7% | -29.9% | -3.5% | -4.3% | -3.8% | +8.7% | — |
| May 7, 2025 | AMC | -0.10 | -0.10 | +0.0% | 2.74 | -10.6% | -11.3% | -2.9% | -3.8% | -3.1% | +0.0% | — |
| Mar 11, 2025 | AMC | -0.12 | -0.10 | +16.7% | 3.47 | -10.4% | -8.4% | -3.8% | +7.5% | -0.9% | -2.1% | — |
| Nov 6, 2024 | AMC | -0.13 | -0.11 | +15.4% | 3.88 | +3.4% | -10.8% | -2.0% | +5.6% | -1.1% | +0.3% | — |
| Aug 6, 2024 | AMC | -0.14 | -0.09 | +35.7% | 4.45 | +4.0% | -8.3% | +2.5% | +0.0% | -3.6% | +0.2% | — |
| May 7, 2024 | AMC | -0.14 | -0.09 | +35.7% | 3.93 | +0.3% | +18.1% | +1.9% | +0.2% | -0.6% | -3.6% | — |
| Mar 12, 2024 | AMC | -0.10 | -0.05 | +50.0% | 3.98 | +1.8% | +4.5% | +1.0% | +2.6% | -3.2% | +7.0% | — |
| Nov 8, 2023 | AMC | -0.10 | -0.11 | -10.0% | 3.35 | -3.0% | -3.3% | +1.5% | +5.8% | +6.6% | +0.8% | — |
| Aug 9, 2023 | AMC | -0.10 | -0.10 | +0.0% | 4.36 | -7.3% | -10.3% | -1.8% | +0.0% | -0.8% | -4.2% | — |
| May 10, 2023 | AMC | -0.11 | -0.11 | +0.0% | 4.65 | -12.5% | -19.8% | +2.7% | -1.3% | -2.4% | +3.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | Craig-Hallum | Maintains | Buy → Buy | — | $0.74 | $0.73 | -1.4% | -6.8% | +3.9% | -4.6% | -1.1% | +3.9% |
| Aug 11 | BTIG | Downgrade | Buy → Neutral | — | $1.38 | $1.36 | -1.4% | -4.3% | -3.8% | +8.7% | +2.2% | -3.5% |
| Aug 7 | William Blair | Downgrade | Outperform → Market Perform | — | $2.04 | $1.70 | -16.7% | -29.9% | -3.5% | -4.3% | -3.8% | +8.7% |
| Mar 12 | Stifel | Maintains | Buy → Buy | — | $3.47 | $3.11 | -10.4% | -8.4% | -3.8% | +7.5% | -0.9% | -2.1% |
| Apr 23 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.96 | $3.97 | +0.3% | -4.0% | -1.6% | -1.3% | +0.5% | -1.3% |
| Mar 13 | BTIG | Maintains | Buy → Buy | — | $3.98 | $4.05 | +1.8% | +4.5% | +1.0% | +2.6% | -3.2% | +7.0% |
| Mar 13 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.98 | $4.05 | +1.8% | +4.5% | +1.0% | +2.6% | -3.2% | +7.0% |
| Oct 5 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.27 | $2.53 | -22.6% | -20.5% | +10.0% | +5.2% | +1.7% | -2.3% |
| Mar 28 | Stephens & Co. | Maintains | Overweight → Overweight | — | $4.11 | $4.12 | +0.2% | -0.7% | +8.1% | +6.6% | +5.3% | -3.2% |
| Aug 15 | BTIG | Maintains | Buy → Buy | — | $5.87 | $5.85 | -0.3% | -2.0% | +7.3% | -2.8% | -0.7% | -5.7% |
| Aug 24 | BTIG | Maintains | Buy → Buy | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
| Aug 24 | Stephens & Co. | Maintains | Overweight → Overweight | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
| Aug 24 | Stifel | Maintains | Buy → Buy | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
| Aug 24 | TD Cowen | Maintains | Outperform → Outperform | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
| Aug 24 | William Blair | Maintains | Outperform → Outperform | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
No insider trades available.
8-K · 2.02
!! High
MaxCyte, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A leadership transition to a new CFO effective March 30, 2026 signals potential strategic shifts in financial management and capital allocation that investors should monitor for signs of operational changes or guidance updates.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This boilerplate 8-K/FD disclosure suggests MXCT shared non-material information with investors that won't trigger liability, indicating no significant news requiring incorporation into formal filings.
Mar 24
8-K
Unknown — 8-K Filing
Maxcyte faces delisting risk from Nasdaq unless its stock price recovers above minimum bid requirements, threatening market access and investor confidence.
Mar 20
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 8,867,386 | $14M | Reduced | Dec 2025 |
| 2 | Capricorn Fund Managers Ltd | 8,200,000 | $6M | New | Mar 2026 |
| 3 | Vitruvian Partners Llp | 5,043,356 | $4M | — | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 3,981,816 | $3M | New | Mar 2026 |
| 5 | Mudita Advisors Llp | 3,370,689 | $2M | — | Mar 2026 |
| 6 | Bnp Paribas Asset Management Holding S.a. | 2,773,554 | $2M | — | Mar 2026 |
| 7 | Brooklands Fund Management Ltd | 2,190,020 | $2M | New | Mar 2026 |
| 8 | Renaissance Technologies Llc | 1,993,200 | $1M | Added | Mar 2026 |
| 9 | Peapod Lane Capital Llc | 1,332,193 | $926K | New | Mar 2026 |
| 10 | Aqr Capital Management Llc | 1,221,182 | $858K | Added | Mar 2026 |
| 11 | Jane Street Group, Llc | 528,025 | $818K | Added | Dec 2025 |
| 12 | Stonepine Capital Management, Llc | 1,004,673 | $706K | Added | Mar 2026 |
| 13 | Vanguard Portfolio Management Llc | 889,240 | $625K | New | Mar 2026 |
| 14 | Willis Investment Counsel | 862,758 | $606K | — | Mar 2026 |
| 15 | Northern Trust Corp | 799,709 | $562K | Added | Mar 2026 |
| 16 | Two Sigma Investments, Lp | 608,162 | $427K | Added | Mar 2026 |
| 17 | Nano Cap New Millennium Growth Fund L P | 230,000 | $356K | New | Dec 2025 |
| 18 | George Kaiser Family Foundation | 481,803 | $338K | New | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 403,937 | $284K | Added | Mar 2026 |
| 20 | Citadel Advisors Llc | 333,088 | $234K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$128.8M
Enterprise Value
$25.7M
P/E (TTM)
-2.88x
Forward P/E
—
PEG Ratio
-0.48x
P/B
0.75x
P/S
3.90x
P/FCF
-3.56x
EV/EBITDA
—
Shares Out
106.4M
Financials (TTM)
Revenue
$33.0M
Net Income
-$44.6M
EBITDA
-$38.4M
Free Cash Flow
-$36.2M
Op Cash Flow
-$34.4M
EPS Basic
$-0.42
EPS Diluted
$-0.42
EPS Forward
$-0.26
Gross Margin
68.4%
Op Margin
-131.8%
Net Margin
-135.1%
Balance Sheet
Total Assets
$202.5M
Total Liab.
$31.0M
Total Equity
$171.5M
Cash
$103.0M
LT Debt
$0
Book Value/Sh
$1.61
Debt/Equity
0.10x
Current Ratio
8.30
Quick Ratio
7.77
Returns & Growth
ROE
-26.0%
ROA
-22.0%
ROIC
-23.0%
Rev Growth YoY
-14.5%
EPS Growth YoY
-7.7%
Price Returns
2W
+11.0%
1M
+37.5%
3M
+49.1%
6M
-31.2%
12M
-49.2%
Technicals
52W High
$2.33
52W Low
$0.68
50d MA
$0.99
200d MA
$1.21
RSI (14)
50.00
ATR (14)
$0.07
Beta
1.45
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 26, 2026 1:59pm
· Source: financialmodelingprep.com